Corient Private Wealth LP Acquires 195,312 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Corient Private Wealth increased its Elanco stake by 127.9%, acquiring 195,312 shares to own 348,043 shares valued at approximately $8.6 million. Institutional investors collectively own 97.48% of ELAN.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $29.09, versus the stock’s recent price of $24.16.
• Elanco reported quarterly EPS of $0.34, exceeding the $0.27 consensus estimate, while revenue rose 10.2% year over year to $1.37 billion. Company insiders also purchased 63,198 shares worth about $1.47 million over the past three months.

Corient Private Wealth LP raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 127.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 348,043 shares of the company's stock after acquiring an additional 195,312 shares during the quarter. Corient Private Wealth LP owned about 0.07% of Elanco Animal Health worth $8,565,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ELAN. BlackRock Inc. bought a new position in shares of Elanco Animal Health in the second quarter worth $1,202,198,000. Primecap Management Co. CA acquired a new position in Elanco Animal Health in the second quarter valued at about $1,118,402,000. The Manufacturers Life Insurance Company bought a new stake in Elanco Animal Health during the second quarter worth about $205,636,000. UBS Group AG lifted its position in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock worth $331,669,000 after purchasing an additional 5,961,457 shares during the period. Finally, Sei Investments Co. boosted its position in shares of Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company's stock worth $135,214,000 after acquiring an additional 4,975,721 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ELAN shares. UBS Group boosted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Piper Sandler reiterated an "overweight" rating on shares of Elanco Animal Health in a research report on Monday, June 29th. TD Cowen boosted their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, June 18th. Citigroup raised their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Finally, Weiss Ratings downgraded Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $29.09.

Insider Buying and Selling

In other news, insider Shiv O'neill acquired 3,998 shares of Elanco Animal Health stock in a transaction on Tuesday, August 18th. The stock was acquired at an average cost of $23.58 per share, with a total value of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the firm's stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $23.08 per share, with a total value of $96,936.00. Following the completion of the transaction, the chief financial officer directly owned 137,516 shares of the company's stock, valued at approximately $3,173,869.28. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 63,198 shares of company stock worth $1,473,109 in the last three months. Insiders own 1.14% of the company's stock.

Elanco Animal Health Trading Up 0.2%

NYSE ELAN opened at $24.16 on Monday. The stock has a market capitalization of $12.07 billion, a price-to-earnings ratio of -58.93, a PEG ratio of 1.44 and a beta of 1.67. The business's fifty day moving average is $24.62 and its 200-day moving average is $24.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source